Biotech Values

[turtlepower]

ECYT - To me it seems clear that they initially plan on running just a single trial on FR++ patients ie PROCEED. Financially that may be a sound move since the results may be resoundingly good and ECYT may not need to run an additional trial though if the FDA asks for a 2nd one its going to take longer for EC145 to be commercialized in the US. However if the trials are small then they shouldn't last too long.